Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 10/20 | 0.43 |
| ▸ | CCKAR | P32238 | 8/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | NOTCH1 | P46531 | 2/20 | 0.37 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.37 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9573545 | 0.83 | MEN1 (0.54) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL15608470 | 0.81 | CCKBR (0.56) | CCKBRCCKARNOTCH1NOTCH3 | |
| SCHEMBL15608412 | 0.80 | MEN1 (0.43) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL15629497 | 0.80 | CCKBR (0.55) | CCKBRCCKAR | |
| SCHEMBL16777924 | 0.79 | NOTCH1 (0.41) | CCKBRCCKARNOTCH1NOTCH3RBPJ | |
| SCHEMBL16777947 | 0.72 | NOTCH1 (0.49) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL16777948 | 0.72 | NOTCH1 (0.49) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL8741334 | 0.72 | CCKBR (0.58) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL16777944 | 0.70 | CCKBR (0.40) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL16777950 | 0.68 | NOTCH1 (0.51) | MEN1ALDH1A1KMT2ACCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273014-B2 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150166489-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166489-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF | CNR1, ROR1, RORB | MEN1 1075/4885ALDH1A1 899/4885KMT2A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.